Latest Regulatory News

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Anson Resources has announced a maiden JORC lithium resource of 103,000 tonnes LCE at its Green River Project in Utah, with plans to expand through historic well re-entry and a new collaboration with POSCO for lithium extraction technology.

VHM Limited has secured a crucial mining licence for its Goschen Rare Earths and Mineral Sands Project, alongside key domestic and international partnerships and a successful $8.6 million capital raise.

First Lithium Limited is on the cusp of securing critical mining license renewals in Mali and anticipates releasing its maiden Mineral Resource Estimate this quarter, while managing funding and exploration cost pressures.

Careteq Limited reports a significant reduction in operating cash outflow and modest revenue growth for FY25, while facing delays in its key platform integration and a dispute with the ATO over R&D claims.

PhosCo Ltd has unveiled a significant phosphate discovery at its KM Prospect in Tunisia, featuring thick, shallow mineralisation close to the planned processing plant. This breakthrough could fast-track development and improve project economics at the Gasaat Project.

Beacon Minerals has completed an 8-hole diamond drilling program at its Iguana deposit, revealing significant high-grade gold mineralisation and confirming geotechnical stability for pit designs. These findings set the stage for an updated resource model and future development plans.

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.

Bastion Mining has taken control of over 90% of Xanadu Mines shares through a takeover bid, moving swiftly to compulsory acquisition and setting the stage for the Kharmagtai project’s next phase.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Global Uranium and Enrichment Limited’s investee Ubaryon has sealed a binding agreement with uranium giant Urenco, unlocking a A$5 million investment and technical collaboration to accelerate a novel uranium enrichment technology.

Cavalier Resources progresses its Crawford Gold Project with key milestones including an $11 million stream finance negotiation with Raptor Capital and the appointment of Colin Bald as General Manager of Operations.